SRI-31277 is a thrombospondin 1 (TSP-1) inhibitor with a human target pIC50 of 8.28 nM and in vivo activity, and exhibits a very short plasma half-life with intravenous administration.SRI-31277 inhibits interaction between TSP-1 and the latency-associated peptide (LAP) of latent TGF-beta, blocking TSP-1-mediated TGF-beta activation.SRI-31277 can be used for the research of multiple myeloma and fibrotic conditions[1].
Molecular Weight:
387.47
CAS Number:
[1637468-93-9]
Formula:
C17H33N5O5
Target:
TGF-beta Receptor
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
